$LXRP and Neutrisci Enter Cannabinoid Joint Venture

The JV will be named Ambarii Trade Corporation (or similar) (“Ambarii”) and the initial operations will be fully and equally funded by both Lexaria and Neutrisci. Lexaria and Neutrisci will contribute their respective technologies to Ambarii by way of license agreement, and share profits derived from the JV on a 50/50 basis. While there are no immediate plans to do so, Ambarii will be structured in such a way as to allow for a potential future spin-off to be created which could provide value to shareholders of both Lexaria and Neutrisci.

Ambarii intends to secure licensees in California, Colorado and in Canada to manufacture and sell mouth-melt products containing THC. These products will combine the benefits of each of Lexaria’s and Neutrisci’s existing technologies and ingredient mixes. A licensed California entity is scheduled to manufacture and test a THC version of the products in June, 2017. In more developed legal markets such as California and Colorado, cannabis edibles often comprise 33% – 55% market share of all legal sold cannabis products, making high quality cannabis edibles vitally important to the marketplace.

Ambarii also intends to develop hemp oil based mouth-melt products for distribution through networks including Neutrisci’s existing network of retail distributors as well as other methods. Initial test production runs of the hemp oil variety pterostilbene based products has already achieved positive human focus group results.

“This JV signals a milestone advancement in the cannabis edibles marketplace with the advent of a novel line of healthy, sugar-free mouth-melt products,” commented Chris Bunka, Lexaria CEO. “Lexaria is excited to have reached this agreement to lever its patented palatability and absorption enhancing technology for these unique and promising new product offerings.”

Glen Rehman, President of NeutriSci, stated, “We are thrilled to officially partner with Lexaria. This Agreement represents a giant leap forward for the development, sale and manufacturing of cannabis edibles. Ambarii will deliver an edible product that is not only highly effective, but also a healthy sugar free alternative with the benefits of pterostilbene. The Ambarii product line will be a world first, and will have high appeal to today’s health conscious medicinal and recreational users.”

Lexaria’s unique patented technology allows for more efficient and effective absorption of certain molecules such as cannabinoids, while simultaneously masking and at times even eliminating inherent strong flavours and/or odors typical of those molecules. Lexaria’s technology is extremely cost effective to implement and applicable to a wide spectrum of foods.

About Lexaria
Lexaria Bioscience Corp is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com

About NeutriSci
NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci has focused on the development of several breakthrough nutraceutical products with an initial focus on areas such as heart and cholesterol health, sleep deprivation therapies, immune defense as well as men’s prostate and sexual health. NeutriSci continues to build strong relationships and distribution channels for its BluScience™ and NeuEnergy™ products with retailers throughout the United States. NeutriSci is focusing efforts in strengthening sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers.
www.neutrisci.com